Abstract

Suppressing inflammation has been the primary focus of therapies in autoimmune rheumatic diseases (AIRDs), including rheumatoid arthritis and systemic lupus erythematosus. However, conventional therapies with low target specificity can have effects on cell metabolism that are less predictable. A key example is lipid metabolism; current therapies can improve or exacerbate dyslipidemia. Many conventional drugs also require in vivo metabolism for their conversion into therapeutically beneficial products; however, drug metabolism often involves the additional formation of toxic by-products, and rates of drug metabolism can be heterogeneous between patients. New therapeutic technologies and research have highlighted alternative metabolic pathways that can be more specifically targeted to reduce inflammation but also to prevent undesirable off-target metabolic consequences of conventional antiinflammatory therapies. This Review highlights the role of lipid metabolism in inflammation and in the mechanisms of action of AIRD therapeutics. Opportunities for cotherapies targeting lipid metabolism that could reduce immunometabolic complications and potential increased cardiovascular disease risk in patients with AIRDs are discussed.

MeSH

Pharmaceutical Preparations, Rheumatic Diseases, Therapeutics

Cited by

• Associations between metabolic disorders and Sjögren's disease. Jpn Dent Sci Rev, 2024
• RNA modification: a promising code to unravel the puzzle of autoimmune diseases and CD4 T cell differentiation. Front Immunol, 2025
• Serum lipid profile in systemic lupus erythematosus. Front Immunol, 2025
• Chronic Overlapping Pain Conditions and Nociplastic Pain. medRxiv, 2024
• Ceramides in Autoimmune Rheumatic Diseases: Existing Evidence and Therapeutic Considerations for Diet as an Anticeramide Treatment. Nutrients, 2023
• Systemic lupus erythematosus patients have unique changes in serum metabolic profiles across age associated with cardiometabolic risk. Rheumatology (Oxford), 2024
• Network pharmacology and gut microbiota insights: unraveling Shenling Baizhu powder's role in psoriasis treatment. Front Pharmacol, 2024
• CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities. Front Med (Lausanne), 2022
• Systemic lupus erythematosus and cardiovascular disease. J Intern Med, 2022
• Lipid metabolism in myeloid cell function and chronic inflammatory diseases. Front Immunol, 2025
• Impact of puberty, sex determinants and chronic inflammation on cardiovascular risk in young people. Front Cardiovasc Med, 2023
• Waking Salivary Cortisol Associated with Magnitude of Cholesterol Reduction in Women Fed a Healthy Whole-Food Diet for 8 Weeks. Curr Dev Nutr, 2022
• Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL). Int J Mol Sci, 2022
• Lipidomic Profiling in Synovial Tissue. Front Med (Lausanne), 2022
• Atg5 deficiency in basophils improves metabolism in lupus mice by regulating gut microbiota dysbiosis. Cell Commun Signal, 2025
• Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases. Int J Mol Sci, 2025
• Transcriptomic Analysis of Arachidonic Acid Pathway Genes Provides Mechanistic Insight into Multi-Organ Inflammatory and Vascular Diseases. Genes (Basel), 2024
• The Causal Relationship Between Blood Lipids and Systemic Lupus Erythematosus Risk: A Bidirectional Two-Sample Mendelian Randomization Study. Front Genet, 2022
• Potential Causal Relationship Between Extensive Lipid Profiles and Various Hair Loss Diseases: Evidence From Univariable and Multivariable Mendelian Randomization Analyses. J Cosmet Dermatol, 2025
• Elevated circulating PCSK9 level is associated with 28-day mortality in patients with sepsis: a prospective cohort study. BMC Emerg Med, 2023